459 related articles for article (PubMed ID: 25641072)
21. New treatment options for irritable bowel syndrome with predominant diarrhea.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):25-30. PubMed ID: 27875419
[TBL] [Abstract][Full Text] [Related]
22. Rifaximin: a review of its use in the management of traveller's diarrhoea.
Robins GW; Wellington K
Drugs; 2005; 65(12):1697-713. PubMed ID: 16060706
[TBL] [Abstract][Full Text] [Related]
23. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.
Scarpignato C; Pelosini I
Chemotherapy; 2005; 51 Suppl 1():36-66. PubMed ID: 15855748
[TBL] [Abstract][Full Text] [Related]
24. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.
Peralta S; Cottone C; Doveri T; Almasio PL; Craxi A
World J Gastroenterol; 2009 Jun; 15(21):2628-31. PubMed ID: 19496193
[TBL] [Abstract][Full Text] [Related]
25. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases.
Bajaj JS; Barbara G; DuPont HL; Mearin F; Gasbarrini A; Tack J
Dig Liver Dis; 2018 Aug; 50(8):741-749. PubMed ID: 29807873
[TBL] [Abstract][Full Text] [Related]
26. Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome.
Triantafyllou K; Sioulas AD; Giamarellos-Bourboulis EJ
Mini Rev Med Chem; 2015; 16(3):186-92. PubMed ID: 26202193
[TBL] [Abstract][Full Text] [Related]
27. Use of rifaximin in gastrointestinal and liver diseases.
Shayto RH; Abou Mrad R; Sharara AI
World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
[TBL] [Abstract][Full Text] [Related]
28. Rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea.
Med Lett Drugs Ther; 2015 Aug; 57(1474):109-11. PubMed ID: 26218792
[No Abstract] [Full Text] [Related]
29. Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin.
DuPont HL; Wolf RA; Israel RJ; Pimentel M
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795384
[No Abstract] [Full Text] [Related]
30. Rifaximin treatment for symptoms of irritable bowel syndrome.
Fumi AL; Trexler K
Ann Pharmacother; 2008 Mar; 42(3):408-12. PubMed ID: 18303148
[TBL] [Abstract][Full Text] [Related]
31. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.
Pimentel M; Cash BD; Lembo A; Wolf RA; Israel RJ; Schoenfeld P
Dig Dis Sci; 2017 Sep; 62(9):2455-2463. PubMed ID: 28589238
[TBL] [Abstract][Full Text] [Related]
32. Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome.
Zhuang X; Tian Z; Li L; Zeng Z; Chen M; Xiong L
Front Microbiol; 2018; 9():1600. PubMed ID: 30090090
[TBL] [Abstract][Full Text] [Related]
33. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation.
Schey R; Rao SS
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):461-4. PubMed ID: 21780893
[TBL] [Abstract][Full Text] [Related]
34. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Brenner DM; Sayuk GS
Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
[TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.
Schoenfeld P; Pimentel M; Chang L; Lembo A; Chey WD; Yu J; Paterson C; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2014 May; 39(10):1161-8. PubMed ID: 24697851
[TBL] [Abstract][Full Text] [Related]
36. Rifaximin: new therapeutic indication and future directions.
Rivkin A; Gim S
Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
[TBL] [Abstract][Full Text] [Related]
37. Antibiotics and Probiotics for Irritable Bowel Syndrome.
Goodoory VC; Ford AC
Drugs; 2023 Jun; 83(8):687-699. PubMed ID: 37184752
[TBL] [Abstract][Full Text] [Related]
38. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP
Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177
[TBL] [Abstract][Full Text] [Related]
39. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome.
Zeber-Lubecka N; Kulecka M; Ambrozkiewicz F; Paziewska A; Goryca K; Karczmarski J; Rubel T; Wojtowicz W; Mlynarz P; Marczak L; Tomecki R; Mikula M; Ostrowski J
Gut Microbes; 2016 Sep; 7(5):397-413. PubMed ID: 27662586
[TBL] [Abstract][Full Text] [Related]
40. Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome.
Vicari E; Salemi M; Sidoti G; Malaguarnera M; Castiglione R
Nutrients; 2017 Nov; 9(11):. PubMed ID: 29099760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
